China’s Shanghai Henlius Biotech has announced the approval of its HLX04 bevacizumab biosimilar by the country’s National Medical Products Administration, marking the company’s fourth biosimilar approval overall.
The rival to Avastin is indicated for the treatment of metastatic colorectal cancer and unresectable, locally advanced, recurrent or metastatic...






